DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Movantik is a drug marketed by Redhill and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and fourteen patent family members in forty-one countries.
The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.
Movantik was eligible for patent challenges on September 16, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2032. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
Summary for MOVANTIK
|Finished Product Suppliers / Packagers:||3|
|Raw Ingredient (Bulk) Api Vendors:||16|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for MOVANTIK|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for MOVANTIK|
|What excipients (inactive ingredients) are in MOVANTIK?||MOVANTIK excipients list|
|DailyMed Link:||MOVANTIK at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for MOVANTIK
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MOVANTIK
Identify potential brand extensions & 505(b)(2) entrants
|University of Missouri-Columbia||Phase 4|
|University of Tennessee, Chattanooga||N/A|
|Camille Ladanyi MD||N/A|
MOVANTIK is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MOVANTIK is ⤷ Try it Free.
This potential generic entry date is based on patent ⤷ Try it Free.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting MOVANTIK
|Country||Patent Number||Estimated Expiration|
|Portugal||1436012||⤷ Try it Free|
|Portugal||2621496||⤷ Try it Free|
|Cyprus||1117376||⤷ Try it Free|
|Cuba||20130047||⤷ Try it Free|
|Croatia||P20140361||⤷ Try it Free|
|Portugal||1694363||⤷ Try it Free|
|Serbia||54488||⤷ Try it Free|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1694363||PA2015019,C1694363||Lithuania||⤷ Try it Free||PRODUCT NAME: NALOKSEGOLAS, KONKRECIAI NALOKSEGOLO OKSALATO DRUSKA; REGISTRATION NO/DATE: EU/1/14/962 20141208|
|1694363||27/2015||Austria||⤷ Try it Free||PRODUCT NAME: NALOXEGOL, GEGEBENENFALLS IN FORM EINES THERAPEUTISCH VERTRAEGLICHEN SALZES, INSBESONDERE ALS OXALAT; REGISTRATION NO/DATE: EU/1/14/962 20141208|
|1694363||C300737||Netherlands||⤷ Try it Free||PRODUCT NAME: NALOXEGOL ALSMEDE DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/14/962 20141208|
|1694363||592||Finland||⤷ Try it Free|
|1694363||PA2015019||Lithuania||⤷ Try it Free||PRODUCT NAME: NALOXEGOLUM; REGISTRATION NO/DATE: EU/1/14/962 20141208|
|1694363||SPC/GB15/026||United Kingdom||⤷ Try it Free||PRODUCT NAME: NALOXEGOL OXALATE; REGISTERED: UK EU/1/14/962/001-011 20141210|
|1694363||2015/024||Ireland||⤷ Try it Free||PRODUCT NAME: NALOXEGOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE OXALATE SALT OF THE ALPHA-EPIMER OF NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141208|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|